[go: up one dir, main page]

HK1223852A1 - 睪丸酮凝膠組合物及相關方法 - Google Patents

睪丸酮凝膠組合物及相關方法 Download PDF

Info

Publication number
HK1223852A1
HK1223852A1 HK16112308.4A HK16112308A HK1223852A1 HK 1223852 A1 HK1223852 A1 HK 1223852A1 HK 16112308 A HK16112308 A HK 16112308A HK 1223852 A1 HK1223852 A1 HK 1223852A1
Authority
HK
Hong Kong
Prior art keywords
gel compositions
related methods
testosterone gel
testosterone
gel
Prior art date
Application number
HK16112308.4A
Other languages
English (en)
Inventor
Harish K. Pimplaskar
Original Assignee
Upsher-Smith Laboratories, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upsher-Smith Laboratories, Llc filed Critical Upsher-Smith Laboratories, Llc
Publication of HK1223852A1 publication Critical patent/HK1223852A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16112308.4A 2013-12-13 2014-12-11 睪丸酮凝膠組合物及相關方法 HK1223852A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361915742P 2013-12-13 2013-12-13
US201361915742P 2013-12-13
US201414177765 2014-02-11
US14/177,765 US8785426B1 (en) 2013-12-13 2014-02-11 Testosterone gel compositions and related methods
PCT/US2014/069760 WO2015089289A1 (en) 2013-12-13 2014-12-11 Testosterone gel compositions and related methods

Publications (1)

Publication Number Publication Date
HK1223852A1 true HK1223852A1 (zh) 2017-08-11

Family

ID=51177812

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16112308.4A HK1223852A1 (zh) 2013-12-13 2014-12-11 睪丸酮凝膠組合物及相關方法

Country Status (8)

Country Link
US (3) US8785426B1 (zh)
EP (1) EP3079703A4 (zh)
AU (1) AU2014362275A1 (zh)
CA (1) CA2857286C (zh)
HK (1) HK1223852A1 (zh)
SG (1) SG11201604788UA (zh)
WO (1) WO2015089289A1 (zh)
ZA (1) ZA201604587B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3332787A4 (en) * 2015-09-30 2018-08-01 Fujifilm Corporation Transdermally absorbable composition
US20200101085A1 (en) * 2018-09-28 2020-04-02 Joel Studin Transpore delivery of drugs and uses thereof
BE1030538B1 (nl) * 2022-05-18 2023-12-19 Bogaert Gina Van Liposomaal preparaat met ingekapselde hormonen, werkwijze voor de productie en gebruik ervan

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US5332577A (en) 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
WO1993025168A1 (en) 1992-06-11 1993-12-23 Theratech, Inc. The use of glycerin in moderating transdermal drug delivery
US5885565A (en) 1993-03-19 1999-03-23 Cellegy Pharmaceuticals Inc. Methods for inducing phase separation of epithelial lipid bilayers
US5760096A (en) 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers
US6019997A (en) 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
US5908619A (en) 1997-01-09 1999-06-01 Minnesota Mining And Manufacturing Company Hydroalcoholic compositions thickened using surfactant/polymer complexes
DE69840426D1 (de) 1997-11-10 2009-02-12 Strakan Int Ltd Penetrationsfördernde und irritationsvermindernde Systeme mit Testosteron
AU1728099A (en) 1997-12-22 1999-07-12 Alza Corporation Monoglyceride and ethyl palmitate permeation enhancer compositions
KR100684055B1 (ko) 1998-03-19 2007-02-16 머크 앤드 캄파니 인코포레이티드 생물활성 물질의 방출 조절용 액체 중합체성 조성물
US6733767B2 (en) 1998-03-19 2004-05-11 Merck & Co., Inc. Liquid polymeric compositions for controlled release of bioactive substances
WO2002011768A1 (en) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
CA2746787A1 (en) 2000-08-30 2002-03-07 Unimed Pharmaceuticals, Llc. Method of increasing testosterone and related steroid concentrations in women
TWI331522B (en) 2001-06-22 2010-10-11 Cpex Pharmaceuticals Inc Pharmaceutical composition
JP3909812B2 (ja) 2001-07-19 2007-04-25 富士フイルム株式会社 表示素子及び露光素子
AU2002340120A1 (en) 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
FR2832311B1 (fr) 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
JP5160018B2 (ja) 2002-06-25 2013-03-13 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド 非晶質医薬組成物を用いる経皮送達速度調節
FR2851470B1 (fr) 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
EP1663142A2 (en) 2003-06-23 2006-06-07 MacroChem Corporation Compositons and methods for topical administration
US20070287688A1 (en) 2003-07-11 2007-12-13 Macro Chem Corporation Pharmaceutical Compositions for Topical Application
DK2450041T3 (en) 2005-10-12 2018-11-19 Unimed Pharmaceuticals Llc Enhanced testosterone gel for use in the treatment of hypogonadism
US20120022033A1 (en) * 2010-07-23 2012-01-26 Biosante Pharmaceuticals, Inc. Methods for decreasing cardiovascular risk in postmenopausal women
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013130535A1 (en) 2012-02-27 2013-09-06 Newgen Biopharma Corporation Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same

Also Published As

Publication number Publication date
CA2857286A1 (en) 2014-11-21
US20150164913A1 (en) 2015-06-18
US20160310508A1 (en) 2016-10-27
ZA201604587B (en) 2017-11-29
AU2014362275A1 (en) 2016-07-21
US9662340B2 (en) 2017-05-30
SG11201604788UA (en) 2016-07-28
EP3079703A1 (en) 2016-10-19
US8785426B1 (en) 2014-07-22
WO2015089289A1 (en) 2015-06-18
US9295675B2 (en) 2016-03-29
EP3079703A4 (en) 2017-07-12
CA2857286C (en) 2016-01-12

Similar Documents

Publication Publication Date Title
IL273592A (en) A multispecific antigen-binding molecule that has the function-changing activity of a cofactor for blood coagulation factor viii (fviii), and a pharmaceutical formulation containing the molecule as an active ingredient
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EP3016653A4 (en) Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
WO2015023649A3 (en) Peptides for enhancing transdermal delivery
BR112014021531A8 (pt) composto, composição farmacêutica e usos dos mesmos
EA201492011A1 (ru) Безводные фармацевтические составы для местного применения
EP3714887A4 (en) PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION AND RELATED PREPARATION PROCESS
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
EP3093023A4 (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
EP3613419A4 (en) PHARMACEUTICAL COMPOSITION WITH INDIRUBY DERIVATIVE AS THE ACTIVE SUBSTANCE
WO2014121764A3 (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
EP3480186A4 (en) NOVEL ARYLETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THIS DERIVATIVE AS ACTIVE INGREDIENT
WO2014121048A3 (en) Topical compositions and methods for making and using same
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX368268B (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
WO2014122460A3 (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
WO2015001163A3 (es) Nanopartículas lipídicas para la cicatrización de heridas
MX2015001387A (es) Formulacion transdermica que contienen inhibidores de ciclooxigenasas (cox).
MX2014014579A (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
WO2014166836A8 (en) Growth hormone compound formulation